VOC Health enters exclusive licensing agreement to develop devices capable of detecting early-stage cancers and COVID-19

VOC Health Inc. acquires exclusive rights to a portfolio of intellectual property owned by the University of Pennsylvania covering several nanotechnologies.

Prostate Cancer detected with perfect accuracy in first, small sample test.

Prostate becomes the third cancer detected by VOC Health using volatile organic compounds (VOCs) in blood samples, along with the detection of COVID-19 from sweat.

COVID-19 Successfully Detected Using Body Odor
Slide 1
New Device Detects Stage I Cancer in a Blood Sample

Our nanosensor detected ovarian cancer in 58 lab-bench tests at the University of Pennsylvania with 95% sensitivity and 99% specificity.

Slide 3
Detecting Cancer with Scent (VOCs)

Volatile Organic Compounds (VOCs) are molecules released in large numbers from liquids and solids. Most scents are, in fact, VOCs. Cancers cause bio-responses in the body that produce VOCs. We're using them for detection.

previous arrowprevious arrow
next arrownext arrow

VOC Health’s mission is to detect disease at the earliest possible stage,
to increase survivability and lower healthcare costs.
Watch a video about our Stage I Cancer Detection:

For more information, contact:
Richard Postrel
CEO & Chief Innovation Officer
(305) 865-7000